Literature DB >> 846520

Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy.

A G Smals, L V Beex, P W Kloppenborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 846520     DOI： 10.1056/nejm197704212961617

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 2.  Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure.

Authors:  Olivier Boutaud; L Jackson Roberts
Journal:  Free Radic Biol Med       Date:  2010-10-27       Impact factor: 7.376

3.  Rhabdomyolysis. The role of diagnostic and prognostic factors.

Authors:  Eran Keltz; Fahmi Yousef Khan; Gideon Mann
Journal:  Muscles Ligaments Tendons J       Date:  2014-02-24

4.  Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.

Authors:  A Bardosi; P Scheidt; H H Goebel
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

5.  [Rhabdomyolysis with acute renal failure due to bezafibrate].

Authors:  H Heidemann; K D Bock
Journal:  Klin Wochenschr       Date:  1981-04-15

6.  Treatment of severe 2,4-D and mecoprop intoxication with alkaline diuresis.

Authors:  L F Prescott; J Park; I Darrien
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

Review 7.  Aspects of mixed connective tissue disease: a review.

Authors:  T H Dent; V W Johnson
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

Review 8.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

Authors:  Jianyong Wu; Yan Song; Heng Li; Jianghua Chen
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 3.064
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.